SCHEMBL1170767

SCHEMBL1170767

[CH2]NC(=O)OCCCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1170167 0.93 EPHX1 (0.64)
SCHEMBL28428629 0.91 EPHX1 (0.68)
SCHEMBL6500219 0.86
SCHEMBL16824229 0.81 EPHX1 (0.59)
SCHEMBL590532 0.81 EPHX1 (0.59)
SCHEMBL9395279 0.80 EPHX1 (0.53)
SCHEMBL968307 0.79
SCHEMBL383296 0.79
SCHEMBL988903 0.78 ACHE (0.60)
SCHEMBL361310 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2976340-A1 CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-01-27 EP claimed
WO-2014146490-A1 CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-09-25 WO claimed
EP-1863756-A1 BIARYL DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-12 EP claimed
WO-2006102645-A1 BIARYL DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-09-28 WO claimed
WO-2005016883-A2 ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-02-24 WO claimed
EP-0942924-A2 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 1999-09-22 EP claimed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS 1998-08-20 WO claimed
WO-1998022494-A2 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO claimed
US-5693634-A FOR SYSTEMIC AND TOPICAL TREATMENT OF HUMANS AND ANIMALS; VETERINARY MEDICINE GLAXO WELLCOME S.P.A. (IT) 1997-12-02 US claimed
EP-0773945-A1 ACYL IMIDAZOPYRIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1997-05-21 EP claimed
EP-0728135-A1 UREA DERIVATIVES GLAXO WELLCOME S.p.A. (IT) 1996-08-28 EP claimed
EP-0722449-A1 BOROPEPTIDE INHIBITORS OF THROMBIN WHICH CONTAIN A SUBSTITUTED PYRROLIDINE RING THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-07-24 EP claimed
WO-1996003404-A1 ACYL IMIDAZOPYRIDINES BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1996-02-08 WO claimed
WO-1995013278-A1 UREA DERIVATIVES GLAXO WELLCOME S.P.A. (IT) 1995-05-18 WO claimed
WO-1995009859-A1 BOROPEPTIDE INHIBITORS OF THROMBIN WHICH CONTAIN A SUBSTITUTED PYRROLIDINE RING THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-04-13 WO claimed
EP-0390693-A1 Thioformamide derivatives RHONE-POULENC SANTE (FR) 1990-10-03 EP claimed
EP-0303934-A1 2-Cyano-2-oximino-acetamides BAYER AG (DE) 1989-02-22 EP claimed
EP-3400223-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES Syngenta Participations AG (CH) 2018-11-14 EP disclosed
US-4195090-A ADRENERGIC BLOCKING AGENTS CIBA-GEIGY CORPORATION (US) 1980-03-25 US disclosed
US-4115575-A CARDIOVASCULAR DISORDERS CIBA-GEIGY CORPORATION (US) 1978-09-19 US disclosed